Company intelligence / Profile preview

AusperBio

San Mateo, California, United Statesausperbio.com ↗

Ownership: Private
Development stage: Phase 2

Overview

AusperBio’s lead program AHB‑137 has completed a global Phase Ib trial and is in multiple Phase II trials in China. Interim Phase IIa data were presented at the AASLD conference in late 2024. The company reports promising preclinical and early clinical results for its dual-mechanism ASO approach to HBV cure.

Therapeutic areas: Infectious Diseases
Modalities: Antisense oligonucleotides (ASO)
Industry: Biotech

Drug pipeline

8 assets

AHB-137

7 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on AusperBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AusperBio.

Explore the full profile